Legal
Refine Search
Pharmaceutical
Ireland-headquartered Avadel Pharmaceuticals saw its shares gain more than 12% to $8.03 on Friday, after it announced a positive patent dispute ruling. 21 November 2022
Pharmaceutical
Switzerland’s Relief Therapeutics was up 6.5% this morning after it announced definitive settlement agreements with NRx Pharmaceuticals to resolve their pending litigation. 14 November 2022
Pharmaceutical
Following a four to zero vote for the action, the US Federal Trade Commission (FTC) has filed an amicus brief with the US District Court for the District of Delaware in the case of US drugmaker Jazz Pharmaceuticals versus Ireland-incorporated Avadel Pharmaceuticals 12 November 2022
Generics
New York Attorney General Letitia James last Friday marked a major milestone in her fight against the opioid crisis in New York state, when she announced that her office has secured up to $523 million from the US subsidiary and affiliates of Israeli generics giant Teva Pharmaceutical Industries for their role in fueling the opioid crisis. 7 November 2022
Pharmaceutical
US neurological diseases specialist Acorda Therapeutics saw its shares go stratospheric yesterday, after it revealed it has been awarded $16.5 million by an arbitral panel following a dispute with Ireland-incorporated drugmaker Alkermes over licensing royalties for the multiple sclerosis drug Ampyra (dalfampridine). 18 October 2022
Pharmaceutical
The challenges of tackling international crime with national law enforcement are legion, writes John Binns, partner in the Financial Crime team at BCL Solicitors, in an Expert View piece. He considers how Interpol’s Operation Pangea illustrates how they can be overcome in the context of the global fight against illicit medicines. 17 October 2022
Pharmaceutical
The European Commission has informed Israel-based generics behemoth Teva Pharmaceutical Industries of its preliminary view that the company has breached EU antitrust rules by engaging in practices intended to delay competition to its blockbuster multiple sclerosis drug Copaxone (glatiramer acetate). 10 October 2022
Biotechnology
In the USA, Eli Lilly and Teva Pharmaceutical will meet in court after a federal judge slapped down an attempt to invalidate three of the latter’s patents. 6 October 2022
Biotechnology
US biotech Gilead Sciences has filed an anti-counterfeiting lawsuit against pharmaceutical suppliers and distributors for selling what it describes as ‘fake’ versions of its HIV medications. 30 September 2022
Pharmaceutical
Japanese drug major Sumitomo Pharma has filed an appeal with the US Court of Appeals for the Federal Circuit (CAFC) seeking revocation of the decision of the US Patent and Trademark Office (USPTO) relating to the proprietary atypical antipsychotic agent Latuda (lurasidone HCl tablets). 29 September 2022
Biotechnology
In what is the biggest ‘whistleblower’ settlement, US major Biogen has agreed to pay $900 million to resolve allegations that it caused the submission of false claims to Medicare and Medicaid by paying kickbacks to physicians to induce them to prescribe its multiple sclerosis drugs. 27 September 2022
Generics
Astellas Pharma saw its share gain 1.6% in early trading, though it later drifted back, as it revealed it has won a reprieve in its patent dispute with generics and biosimilar injectables specialist Hospira, albeit just short term. 26 September 2022
Generics
There was positive news from US pharma giant Merck & Co this morning, with respect to patent litigation relating to its blockbuster diabetes drug franchise. 22 September 2022
Biotechnology
Investors are jittery after the sudden departure of French drugmaker Servier from a collaboration in oncology with San Francisco’s Allogene Therapeutics. 22 September 2022
Pharmaceutical
The US Court of Appeals for the Federal Circuit (CAFC) has denied its petition to rehear the negative decision regarding the validity of US Patent No 9,187,405, covering a dosing regimen for 0.5mg of its blockbuster multiple sclerosis drug Gilenya (fingolimod), Swiss pharma giant Novartis announced this morning. 21 September 2022
Biosimilars
The Initiative for Medicines, Access, and Knowledge (I-MAK), a campaign group seeking to drive down the cost of medicines, has taken aim at pharma firms’ protection of their patents. 16 September 2022
Pharmaceutical
The Basel headquarters of pharma giant Novartis were raided at dawn earlier this week by the Swiss Competition Commission (COMCO). 15 September 2022
Generics
A breakthrough on the litigation front will extend exclusivity for certain of Gilead Sciences’ HIV meds by around six or seven years. 13 September 2022
Pharmaceutical
Johnson & Johnson and its USA-based Janssen Pharmaceutical Companies have announced a settlement agreement with the State of New Hampshire and its participating subdivisions resolving their opioid-related claims against the company. 2 September 2022
Biotechnology
Threatening to upset Pfizer’s dominance of the multi-billion dollar coronavirus vaccine market, Moderna is today starting legal action against the firm, claiming patent infringement. 26 August 2022
Pharmaceutical
Danish pharma major Novo Nordisk says that it has become aware of several hundred units of Ozempic (semaglutide) injection 1 mg distributed outside its authorized supply chain in the USA. 15 April 2025
Generics
A Texan drug compounder cannot rely on federal law to avoid a lawsuit over copycat sales of a rheumatoid arthritis treatment, clearing the way for Zyla Life Sciences to pursue claims under state competition laws. 14 April 2025
Biosimilars
Swiss generic and biosimilar medicines firm Sandoz today announced it has filed an antitrust lawsuit in the USA against Amgen for extending and entrenching the dominant market position of its blockbuster medicine, Enbrel (etanercept), first approved by the US Food and Drug Administration (FDA) in 1998. 14 April 2025
Pharmaceutical
Indian drugmaker Sun Pharmaceutical shares were buzzing in trade on the last trading day of the week to April 11, rising as much as 5%. 11 April 2025
Pharmaceutical
Ireland’s government remains confident in its ability to retain the country’s strategic position in pharmaceutical manufacturing, despite rising tensions between the European Union and the United States over trade policy. 8 April 2025
Pharmaceutical
With two new lawsuits, Eli Lilly has escalated its legal campaign against the makers of unauthorized versions of its diabetes and weight-loss drugs, Mounjaro (tirzepatide) and Zepbound (tirzepatide), challenging inroads made by drug compounders in what has become a highly lucrative market. 3 April 2025
Biotechnology
Germany-headquartered CureVac late Thursday announced that the European Patent Office (EPO) has confirmed the validity of CureVac's European patent EP 3 708 668 B1 subject to amendments to specify the scope of protection. 28 March 2025
Biotechnology
Sinovac Biotech, a China-based biopharmaceutical company specializing in vaccine development, has been urged by shareholder Heng Ren Partners to distribute $8.9 billion in cash reserves to shareholders and to resume trading of its shares on Nasdaq. 24 March 2025
Biotechnology
Danish biotech on Saturday revealed that US pharma major (AbbVie has filed a complaint in the US District Court for the Western District of Washington, naming Genmab, ProfoundBio and former AbbVie employees as defendants. 22 March 2025
Pharmaceutical
Purdue Pharma has filed a Chapter 11 Plan of Reorganization and related disclosure statement with the US Bankruptcy Court for the Southern District of New York. 20 March 2025
Pharmaceutical
As the new White House seeks to push ahead with swingeing cuts to government spending, a federal judge in Massachusetts has thrown a wrench in the works. 6 March 2025
Biotechnology
The US Patent Trial and Appeal Board handed a massive victory to Pfizer and BioNTech on Wednesday, as it invalidated two of Moderna patents covering its Spikevax COVID-19 vaccine, which the challengers stand accused of infringing, according to media reports. 6 March 2025
Biotechnology
Roivant Sciences portfolio company Genevant Sciences and Canada’s Arbutus Biopharma yesterday filed five international lawsuits seeking to enforce patents protecting their innovative LNP technology against Moderna, and certain affiliates. 4 March 2025
Biosimilars
Johnson & Johnson has taken legal action against Samsung Bioepis, accusing the South Korean biotech of violating a settlement agreement by authorizing a third party to market a private-label biosimilar version of Stelara (ustekinumab). 27 February 2025
Pharmaceutical
A group representing compounding pharmacies has filed a lawsuit against the US Food and Drug Administration, arguing that the agency acted unlawfully when it removed Novo Nordisk’s semaglutide-based drugs Ozempic (semaglutide) and Wegovy (semaglutide) from the official shortage lst. 27 February 2025
Pharmaceutical
Danish pharma major Novo Nordisk has sued KBP Biosciences and its founder and executive chairman, Huang Zhenhua, for $830 million in an application to the Singapore International Commercial Court. 19 February 2025
Pharmaceutical
AstraZeneca, Moderna and Novo Nordisk have breached the Association of the British Pharmaceutical Industry (ABPI) Code of Practice for the Pharmaceutical Industry. 17 February 2025
Pharmaceutical
A federal judge has temporarily blocked the National Institutes of Health (NIH) from implementing research funding cuts in 22 states after a lawsuit argued the move would cripple studies on cancer, Alzheimer’s, and other diseases. 11 February 2025
Pharmaceutical
Robert F Kennedy Jr faced pointed questioning during his nomination hearing for secretary of health and human services, as lawmakers sought to reconcile his past controversial statements with the more evidence-based approach he now appears to endorse. 31 January 2025
Biosimilars
US biotech major Amgen =announced that it has reached resolution of its patent infringement litigation related to South Korea-based Celltrion’s denosumab biosimilar products, Amgen brands Prolia and Xgeva. 29 January 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze